1. Home
  2. Directory
  3. North Carolina
  4. Cary
  5. Optometrist
  6. NPI Profile
  7. Prescriptions 1164890521

DR. MICHAEL ANDREW SAMUELS OD
Prescription History 1164890521
Optometrist in Cary, NC

NPI Status: Active since September 02, 2015

Contact Information

229 CROSSROADS BLVD
CARY, NC
ZIP 27518
Phone: (919) 233-8500
Fax: (919) 233-9783

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. MICHAEL ANDREW SAMUELS OD, an active Optometrist specialist practicing in Cary, NC. Our medical registry currently tracks 8 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 214 documented patient claims. Among these therapy options, the most frequently utilized medication is Xiidra, which accounts for 45 claims alone.

Medication Index

C
L
R
T
V
X
No matching medications currently found on file.

Combigan

Generic Formulation: Brimonidine Tartrate/TimololSpecialty: Optometry
Provider Metrics Summary
Total Claims 18
30-Day Fills 32.0
Days Supply 888
NC State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills62.9
Peer Average Days Supply1,777
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.0% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,584.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$365.82

State Avg Cost Per Claim

$365.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of brimonidine tartrate and timolol maleate. The combined ADRENERGIC ALPHA2 RECEPTOR AGONIST and ADRENERGIC BETA-ANTAGONIST activity of these drugs reduce INTRAOCULAR PRESSURE in GLAUCOMA patients.

Therapeutic Applications

This combination medication is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This product contains brimonidine and timolol. These medications are used together when 1 drug is not controlling the pressure inside the eye. Brimonidine works by allowing better fluid drainage from within the eye and also by decreasing the amount of fluid formed in the eye. It belongs to a class of drugs known as alpha agonists. Timolol is thought to work by decreasing the amount of fluid formed in the eye. Timolol belongs to a class of drugs known as beta blockers. This medication is not recommended for use in children less than 2 years old due to an increased risk of serious side effects. Ask the doctor or pharmacist for more details.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 34
30-Day Fills 81.3
Days Supply 2,438
NC State Average Benchmarks
Peer Average Claims152.0
Peer Average 30-Day Fills276.6
Peer Average Days Supply7,930
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 77.6% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,067.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$31.39

State Avg Cost Per Claim

$22.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Lotemax Sm

Generic Formulation: Loteprednol EtabonateSpecialty: Optometry
Provider Metrics Summary
Total Claims 38
30-Day Fills 41.2
Days Supply 902
NC State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills40.9
Peer Average Days Supply1,016
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,604.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$279.08

State Avg Cost Per Claim

$255.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An androstadiene derivative corticosteroid that is used as an ANTI-ALLERGIC AGENT for the treatment of inflammatory and allergic eye conditions.

Therapeutic Applications

This medication is used to temporarily relieve seasonal allergy symptoms of the eyes such as swelling, redness, and itching. Loteprednol belongs to a class of drugs known as corticosteroids.

Lumigan

Generic Formulation: BimatoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 21
30-Day Fills 33.3
Days Supply 974
NC State Average Benchmarks
Peer Average Claims60.0
Peer Average 30-Day Fills100.7
Peer Average Days Supply2,874
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.0% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,854.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$469.26

State Avg Cost Per Claim

$435.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

Bimatoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Restasis

Generic Formulation: CyclosporineSpecialty: Optometry
Provider Metrics Summary
Total Claims 13
30-Day Fills 34.0
Days Supply 1,020
NC State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills76.7
Peer Average Days Supply2,263
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.5% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $23,281.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,790.92

State Avg Cost Per Claim

$1,145.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Tyrvaya

Generic Formulation: Varenicline TartrateSpecialty: Optometry
Provider Metrics Summary
Total Claims 31
30-Day Fills 41.0
Days Supply 1,230
NC State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills17.3
Peer Average Days Supply504
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 93.8% higher than the standard regional baseline profile for NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $26,785.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$864.03

State Avg Cost Per Claim

$643.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzazepine derivative that functions as an ALPHA4-BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION.

Therapeutic Applications

Varenicline is used by adults to help stop smoking. To increase your chance of success, use this medication with a stop-smoking program that includes education, support, and counseling. Quitting smoking lowers your risk of heart and lung disease, as well as cancer. Varenicline works by blocking nicotine's effects in the brain that make you want to smoke. Discuss the risks and benefits of this medication, as well as other ways to quit smoking (such as nicotine replacement treatment), with your doctor.

Vyzulta

Generic Formulation: Latanoprostene BunodSpecialty: Optometry
Provider Metrics Summary
Total Claims 14
30-Day Fills 16.0
Days Supply 430
NC State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills48.8
Peer Average Days Supply1,378
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 57.6% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,361.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$311.51

State Avg Cost Per Claim

$430.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Latanoprostene bunod is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by controlling the flow of fluid within the eye to maintain a normal pressure.

Xiidra

Generic Formulation: LifitegrastSpecialty: Optometry
Provider Metrics Summary
Total Claims 45
30-Day Fills 102.0
Days Supply 3,060
NC State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills36.2
Peer Average Days Supply1,086
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 95.7% higher than the standard regional baseline profile for NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $72,566.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,612.59

State Avg Cost Per Claim

$1,042.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat dry eye disease.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. MICHAEL ANDREW SAMUELS OD provides transparency into local medical care patterns within Cary, NC.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.